News
In just eight years, the NIH National Institute of Allergy and Infectious Diseases moved from identifying an ultra-rare genetic disorder, CD55 deficiency, hyperactivation of the complement, angiopathic thrombosis, and protein-losing enteropathy (CHAPLE) to FDA approval of its first treatment option
Six NIH technologies that have been developed into commercial products are featured in Federal Technology Transfer 2006, a new booklet from the Federal Laboratory Consortium (FLC). The booklet is a compilation of some of the most promising projects from FLC's member laboratories and agencies during
Tuberculosis (TB) is a disease of mammoth proportions both in human lives lost and economic impact. Although preventative measures in this country have left the US relatively unscathed, TB is the second leading cause of death in adults worldwide. It disproportionately affects populations with poorer
Neglected diseases affect approximately 1 billion people, primarily in developing countries. However, since most R&D is not focused on neglected diseases, very few new treatments are brought to market. Through its partnerships with international public and private institutions, the NIH Office of